Background. Conventional amphotericin B-based antifungal therapy for invasive fusariosis in patients with a hematologic malignancy results in a у70% failure rate. Posaconazole is a broad-spectrum antifungal agent with in vitro and in vivo activity against Fusarium species.
After Aspergillus species, Fusarium species are among the leading fungal pathogens to cause invasive mold infection in patients with underlying hematologic malignancy and in those who have undergone hematopoietic stem cell transplantation (HSCT) [1] [2] [3] . Mortality rates associated with fusariosis have equaled or exceeded 70% [2, 4] , and progression in high-risk patients is often fulminant, leaving a narrow window of opportunity for therapeutic intervention. The primary antifungal therapy is amphotericin B or its lipid formulations [2, 5, 6] ; however, this therapy is of limited efficacy because of its potential toxicity and poor activity against Fusarium organisms in vivo. Other treatment options include voriconazole, which is indicated for the treatment of fusariosis in patients intolerant of or with disease refractory to other therapy.
Posaconazole, a potent extended-spectrum triazole, has been shown to be highly active in vitro against various yeasts and molds, including Fusarium species [7] . Preclinical animal studies further demonstrated the efficacy of posaconazole in the treatment of invasive fusariosis [8] . Initial clinical data suggest that the drug has broad tissue distribution with oral administration and is well tolerated [9] . Here, we describe our clinical experience with posaconazole as salvage treatment for invasive fusariosis in high-risk patients, particularly those with underlying hematologic malignancy.
METHODS

Patient selection.
Twenty-one patients with proven or probable invasive fusariosis who were enrolled in 3 independent, multicenter, open-label clinical trials were included in this retrospective analysis. All cases were required to fulfill the criteria of the European Organisation for Research and Treatment of Cancer/National Institute of Allergy and Infectious Diseases Mycoses Study Group for proven or probable invasive fungal infection [10] . All patients were considered to be intolerant of or have fusariosis refractory to conventional antifungal therapy as defined in the respective study protocols; therefore, posaconazole was considered salvage treatment. Patients with refractory infection had to have received conventional antifungal therapy for at least 7 days. However, if the investigator believed that the infection was progressing, and alternative therapy was necessary, salvage therapy could begin sooner than 7 days. Intolerance to conventional antifungal therapy was defined as severe infusion-related toxicity, nephrotoxicity (serum creatinine level 12 times the upper limit of normal or at least double the baseline value), other organ dysfunction, or high risk of toxicity, as determined on the basis of underlying disease or concomitant medications.
Study design. All patients received at least 1 dose of posaconazole, which was given as an oral suspension (800 mg per day) in 2 or 4 divided doses. Compliance with treatment was verified through tracking of study drug dispensing and return by a staff member at each study center. To enhance bioavailability, patients were encouraged to take posaconazole with food or to receive it with enteral feedings that had high fat content. Patients were treated for up to 12 months. Concurrent use of other systemic antifungal agents (intravenous or oral) was not permitted. Clinical information that was obtained included age; sex; underlying disease, including transplantation status (HSCT or solid organ transplantation); site of infection; neutropenic status at baseline and during therapy; presence of graft-versus-host disease; previous antifungal therapy; duration of posaconazole treatment; renal and hepatic function test results; reason for enrollment (refractory, intolerant, or both); corticosteroid use; myelosuppressive and immunosuppressive therapies; use of growth factors; and date and cause of death.
The primary efficacy end point was global response at end of therapy, as determined by the investigator. Successful response was defined as resolution (complete response) or clinically meaningful improvement (partial response) of all symptoms, signs, and radiographic or bronchoscopic abnormalities associated with invasive fusariosis and negative results of follow-up cultures (if performed). Nonsuccessful response was defined as stable infection (no improvement); deterioration in symptoms, signs, and radiographic or bronchoscopic abnormalities (failure); persistent positive culture results; or inability to determine response.
Definitions and adverse events. Safety was assessed on the basis of the incidence and severity of adverse events, which included the onset of new illness and the exacerbation of preexisting conditions other than the indication under study. Neutropenia was defined as an absolute neutrophil count of !500 cells/mm 3 . Persistent neutropenia was defined as the persistence of neutropenia during the entire course of posaconazole therapy.
RESULTS
Patient characteristics and outcome.
A total of 21 patients (8 were male and 13 were female) with proven or probable fusariosis were included in this analysis. Ages ranged from 10 to 75 years (mean, 44 years), including 3 patients who were !18 years old (2 were 10 years old, and 1 was 14 years old) and 4 elderly patients (i.e., у65 years of age). Most patients (16 [76%] of 21) had hematologic malignancy (leukemia), and 8 (38%) had neutropenia at baseline. Six patients (29%) had a history of HSCT (3 of whom had evidence of graft-versushost disease). Two patients had undergone solid organ transplantation, 2 patients had nonhematologic malignancy (breast cancer), and 6 patients had diabetes. Two had no underlying risk factor for a fungal infection. The response to posaconazole salvage therapy on the basis of underlying characteristics and risk factors is outlined in table 1. The overall success (complete or partial) response to salvage therapy with posaconazole was 48% (10 of 21 patients), and those with disseminated infection (with or without pulmonary involvement) had a 30% response rate (3 of 10 patients). In patients with a localized site of infection, including pulmonary infection, the response rate to salvage therapy ranged from 57% to 75% (table 1) .
Most (20 [95%] of 21) patients who received posaconazole were initially treated with an amphotericin B-based regimen for a median duration of 8 days (range, 2-38 days). Of these 20 patients, all received a lipid-based formulation, and 5 (24%) also received amphotericin B deoxycholate. Of the 21 patients, 17 (81%) met the criteria for refractory infection with or without intolerance to standard antifungal therapy, including 3 with progressing disease. In addition, 4 (19%) of 21 patients either had demonstrated or were at high risk of developing intolerance of standard therapy. Of these 4 patients, 3 had been initially treated with a lipid formulation of amphotericin B for a median duration of 5 days (range, 3-7 days), 2 had also received amphotericin B deoxycholate, and 1 had received no previous antifungal therapy.
The 16 patients with underlying leukemia had received previous therapy with amphotericin B-based regimens alone or in combination with itraconazole and caspofungin (table 2). The overall response rate to posaconazole was 44% (7 of 16 patients). Among the 14 patients (88%) who received posaconazole salvage therapy for 13 days, the response rate was 50%. Only 1 (20%) of the 5 patients with persistent neutropenia responded to posaconazole therapy. In contrast, 6 (67%) of the 9 patients with leukemia and invasive fusariosis who recovered from myelosuppression and received posaconazole salvage therapy for 13 days had a successful outcome. Patients with a history of HSCT had a 17% response rate to salvage therapy (1 of 6 patients). Some patients with a history of HSCT initially responded to posaconazole in the first 2 months of therapy but subsequently experienced treatment failure on progression of their underlying disease.
More patients with acute lymphocytic leukemia than patients with acute myelocytic leukemia or chronic myelocytic leukemia had a response to therapy. For the patients with acute lymphocytic leukemia who received posaconazole therapy for 13 days, the response rate was 83% (5 of 6 patients), compared with 25% (2 of 8 patients) for those with acute myelocytic leukemia or chronic myelocytic leukemia.
Safety. Posaconazole appeared to be safe and generally well tolerated in this population. A transient rash in 1 patient was probably related to posaconazole therapy, and 3 other patients had adverse events that were possibly related. The most common treatment-related adverse events, which occurred in р10% No. of days from the beginning of the study until death (no. of days from the last dose of study drug until death). c The investigator believed that the infection was progressing, and alternative therapy was necessary; therefore, salvage therapy with posaconazole began sooner than 7 days.
of the patient population with invasive fusariosis, were the gastrointestinal disorders of nausea and vomiting (5% each), rash, confusion, and asthenia (5% each). All adverse events were mild to moderate in severity. No QTc prolongation or negative inotropic effects were observed. Although posaconazole produced mild transient elevations in aminotransferase activity in 1 patient, these changes were mild and did not warrant discontinuation of the medication. Posaconazole did not cause any visual disturbances.
DISCUSSION
This retrospective analysis represents the largest report of the efficacy and safety of posaconazole in the treatment of invasive fusariosis. The overall response rate to salvage therapy with posaconazole in patients with invasive fusariosis who were either intolerant of or had infection that was progressing or refractory to conventional antifungal therapy was 48%, a result comparable with those seen for voriconazole in other studies [11] . Furthermore, the complete or partial response rate in leukemic patients with invasive fusariosis who received salvage therapy for 13 days was 50%. It should be noted that, although the authors are well aware of the limitations of a retrospective review for the analysis of an agent, this venue was chosen because active recruitment of eligible patients for a prospective trial solely of invasive fusariosis is problematic, because the infection is relatively rare and must be treated promptly, often before researchers-even those at the same institution-are aware that a patient has the disease.
Conventional antifungal therapy for invasive fusariosis has consisted of an amphotericin B-based regimen, including amphotericin B lipid formulations. However, in immunocompromised patients-particularly those with underlying hematologic malignancy and HSCT recipients-such conventional antifungal therapy has been far from satisfactory. Kontoyiannis et al. [12] recently studied 42 patients with underlying hematologic malignancy (86% of whom had an underlying leukemia) and invasive fusariosis who were treated during the period of 1987-1997 at The M. D. Anderson Cancer Center (Houston, TX). Only 12 (29%) of these patients responded to antifungal therapy, which consisted of an amphotericin B-based regimen for most patients. Administration of high doses of amphotericin B (up to 1.2 mg/kg per day) still resulted in unsuccessful outcomes in some patients [6] , whereas high doses of lipid formulations of amphotericin B (15 mg/kg per day) have shown variable results in other studies [3, 13] . In a recent report, Perfect [14] analyzed data from 26 patients with fusariosis who were treated with amphotericin B lipid complex (median cumulative dose, 5000 mg) as either first-line (n p ) or second-line ( ) therapy. Of these 26 patients, 12 8 n p 20 (46%) were considered to have been cured or to have improved, and 3 had disease that was considered to be stable. The median serum creatinine levels were 1.15 mg/dL at baseline and 1.40 mg/dL at the end of therapy; serum creatinine levels doubled in 4 patients who received amphotericin B lipid complex as second-line therapy.
Voriconazole is also indicated for treatment of fusariosis. In another clinical study that included 11 patients with invasive fusariosis, Perfect et al. [15] demonstrated a global response of 45% with voriconazole; however, stable infection was considered as part of the global response. In contrast, we used morestringent criteria in the definition of successful outcome in that patients who were classified as having stable fusariosis were considered to not have a successful outcome. Voriconazole has been generally well tolerated in the treatment of patients with invasive fungal infections [16] . In the present study, posaconazole was well tolerated; adverse events were mainly mild and included transient rash, gastrointestinal effects, or infrequent changes in liver function test results.
Posaconazole was administered as an oral suspension with food when possible. This method of delivery might limit its use in patients undergoing mechanical ventilation and other critically ill patients. However, the compassionate-use protocols from which some data on invasive fusariosis were derived included patients who received the oral solution via an enteral feeding tube. Oral administration of posaconazole has been shown to be highly effective in animal models of invasive fusariosis, demonstrating organ clearance of fungal organisms and prolongation of survival [8] . In this study of patients with fusariosis, posaconazole was shown to possess a very favorable safety and efficacy profile with convenient oral dosing. Of note, a patient in the current study who presented with keratitis and endophthalmitis due to Fusarium solani responded to treatment with posaconazole suspension, which was both administered orally and applied topically (10 mg/0.1 mL) [17] . After 3 weeks of therapy, the concentration of posaconazole in the vitreous was 0.25 mg/mL, indicating effective penetration of the ocular tissue. The aforementioned attributes of favorable safety, efficacy, and oral bioavailability suggest that posaconazole is well suited to the treatment of chronic invasive fungal infections that require prolonged administration of therapy. Thus, oral posaconazole may provide a real alternative to parenteral amphotericin B-based regimen for the treatment of invasive fusariosis.
Despite the overall relative efficacy, posaconazole was not effective in most (80%) of the patients who had leukemia with persistent neutropenia and in most patients (83%) who underwent HSCT, including 3 with graft-versus-host disease (mild in 1 and moderate or moderately severe in 2). In contrast, 67% of patients with leukemia who recovered from myelosuppression and received posaconazole salvage therapy for 13 days had a successful outcome. The results in patients with neutropenia are consistent with the results from other reports [4, 12, 18] . In our previous experience in patients with hematologic ma-lignancy and invasive fusariosis, antifungal therapy failed in all patients ( ) with persistent neutropenia [12] . Similarly, n p 19 in a multicenter study by Nucci et al. [18] , multivariate analysis showed that only persistent neutropenia and therapy with corticosteroids were significant independent predictors of poor outcome in 84 patients with hematologic malignancy and invasive fusariosis. In another study involving 54 HSCT recipients from 9 hospitals, multivariate analysis demonstrated that persistent neutropenia was the only significant predictor of poor outcome (hazard ratio, 3.65; 95% CI, 1.29-20.36;
) [4] . P p .01 Thus, the results of this retrospective analysis suggest that posaconazole may be an appropriate alternative therapy to the conventional amphotericin B-based regimen for the treatment of invasive fusariosis in patients who are intolerant of or have infection refractory to conventional antifungal therapy.
